Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC
Read more here:
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023.
Here is the original post:
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.
Continue reading here:
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.
Read the original:
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023.
Read the original post:
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome
View post:
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
Highlights:
Go here to see the original:
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of...
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
Read the original post:
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in March.
Here is the original post:
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
___________________________________________(1) Total revenues excluding Trokendi XR net product sales is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP). A reconciliation of this measure to Total revenues (GAAP) is included under the heading "Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR net product sales."(2) Operating earnings (non-GAAP) is a non-GAAP measure and is calculated as Operating earnings (loss) (GAAP) plus amortization of intangible assets, share-based compensation, contingent consideration expense (gain), intangible asset impairment charges, and depreciation. A reconciliation of this measure to Operating earnings (loss) (GAAP) is included under the heading "Reconciliation of GAAP Operating earnings (loss) to Non-GAAP Operating earnings."(3) A reconciliation of the operating earnings (non-GAAP) guidance is included under the heading "Full Year 2024 Financial Guidance - GAAP to Non-GAAP Adjustments."
View original post here:
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results